The recent activity by Fulgent Genetics' executive team highlights ongoing transactions and operational developments at the company.
Gao Hanlin, Chief Scientific Officer (CSO) at Fulgent Genetics, Inc. (NASDAQ:FLGT), executed stock sales on June 2, 2026. These transactions involved the disposal of 1,688 shares of the company’s common stock, totaling approximately $30,190.
The sale was structured to cover tax withholding obligations that arose subsequent to the vesting of certain restricted stock units granted to Mr. Hanlin. The weighted-average price across these sales reached $17.8855 per share, with individual transactions noting prices ranging between $17.63 and $18.10.
Following the reported divestitures, Mr. Hanlin retained a direct holding of 990,374 shares of Fulgent Genetics common stock.
Company Valuation and Financial Metrics
As of recent trading activity, FLGT stock was priced at $18.14, translating to an estimated market capitalization of $515 million. Financial analysis from InvestingPro suggests that FLGT may be undervalued relative to its current pricing, positioning it among listed opportunities deemed